Mitochondrial death inside cardiac or brain cells is a key cause of the extensive secondary phase of additional damage and disability to heart muscle in heart attacks and to brain cells in traumatic brain injuries. NeuroVive's CicloMulsion cremophor-free IV cyclosporine formulation was found in a previous study (NEJM 2008) to reduce infarction size by 40 perecnt by protecting the cardiac mitochondria. This study further examines CicloMulsion's ability to protect cardiac tissue and prevent additional cardiac disability.

Read more http://www.eurekalert.org/pub_releases/2011-04/ccs-fpt041911.php